Acousia Therapeutics: Acousia Therapeutics completes clinical Phase 1 study with its small molecule

Hearing loss company Acousia Therapeutics announced the successful completion of its ACOU085 clinical Phase 1b study, following the final visit of the last patient treated with the highest ACOU085 dose. ACOU085 is a proprietary small-molecule drug candidate under clinical development, with a particular focus on its...